Echinococcus granulosus

In brief

What it is

Echinococcus granulosus is a tapeworm, or cestode: a flat, segmented parasitic worm of the family Taeniidae. Unlike the meters-long tapeworms people picture, the adult is tiny, two to seven millimeters long, with only a head and a few segments, and it lives not in humans but in the gut of a dog ^1,2. What grows in a person is the larva, and it does not look like a worm at all: it is the hydatid cyst, a fluid-filled bladder that slowly swells in an organ, most often the liver or the lung ^2,4. The disease it causes is called cystic echinococcosis, or, by its older name, hydatid disease ¹.

The name covers more than one animal. E. granulosus is now understood as a species complex, Echinococcus granulosus sensu lato, of at least eight genotypes grouped into five species; the genotypes G1 and G3 make up the common E. granulosus sensu stricto, while others, such as the G6 genotype assigned to E. canadensis, cycle through different livestock ^16,20. Its genome was sequenced in 2013 alongside those of three relatives, and the four tapeworm genomes are notable for what they have thrown away: ranging from 115 to 141 megabases, they have shed, across the group, 34 families of homeobox genes and several of the determinants of stem-cell fate that other animals keep, while their metabolism stays finely tuned to scavenge nutrients from the host ⁹.

This page is about two diseases, not one. The dangerous relative is Echinococcus multilocularis, the fox tapeworm, whose larva causes alveolar echinococcosis. Where E. granulosus makes a tidy, rounded cyst, E. multilocularis grows by infiltration, a tumor-like behavior that destroys liver tissue and, untreated, ends in liver failure ^1,3. The two share a page because they share a biology and a reputation: both are larvae of taeniid tapeworms that grow, sometimes enormously, inside human organs, and both are mistaken for cancer ^1,13.

How you get it: a cycle built for dogs and sheep

The parasite's real life is a loop between two animals, and people are an accident. The adult worm lives in the small intestine of a definitive host, a dog for E. granulosus or a fox for E. multilocularis, and sheds eggs in the animal's feces ^2,4. A grazing intermediate host swallows the eggs: sheep and other livestock for the dog tapeworm, small rodents for the fox tapeworm ^2,8. In that animal the egg hatches, the freed embryo bores through the gut wall and travels in the blood to an organ, and there it grows into the larval cyst ⁴. The loop closes when the definitive host eats the infected organ, so the cycle is completed by a dog eating sheep offal, or a fox eating a mouse ^5,8.

A person enters this loop only by swallowing the eggs, usually from soil, water, unwashed food or close contact with an infected dog's coat ². The egg behaves in a human exactly as in a sheep: the embryo crosses the intestinal wall and lodges, most often in the liver, which the blood from the gut reaches first, and next most often in the lungs ^2,4. But the human is a dead end. A person is not eaten by a dog or a fox, so the larva that grows in us never completes the cycle; we are accidental intermediate hosts in whom the parasite simply grows and waits ^4,5.

The worm feeds in a way that matters later for the scan. It has no mouth and no digestive tract; it absorbs its nutrients, glucose included, straight across its outer skin, a living syncytial layer (a single continuous sheet of tissue with no internal cell boundaries) called the tegument, using its own glucose transporters ²¹. In the laboratory the larva is fussy: it survives only in low oxygen with reducing agents, and it grows and makes new protoscoleces only when the culture medium has first been conditioned by liver-tumor cells or other immortal cell lines, a sign that it depends on growth factors supplied by the host ²².

The hydatid cyst

A hydatid cyst is a bladder with a particular architecture. Its wall has an inner germinal layer, only cells thick, which is the living parasite; outside that is an acellular, laminated layer the worm secretes for protection; and outside that again is a fibrous capsule, the pericyst, which is not parasite at all but scar the host lays down around the intruder ¹. The germinal layer buds inward, producing little brood capsules and, inside them, the protoscoleces, the future heads of adult worms; detached protoscoleces and hooklets settle at the bottom of the cyst as a sediment old pathologists called hydatid sand ¹. In long-standing cysts the germinal layer buds whole daughter cysts, so the lesion becomes a cyst within a cyst within a cyst ¹.

Because the cyst grows slowly, often a centimeter or so a year, cystic echinococcosis is usually silent for years and is frequently found by chance on a scan done for something else ^2,4. When it does cause trouble, it is by mechanics rather than poison: a cyst large enough to press on the bile ducts causes jaundice, one in the lung causes cough or chest pain, and one in the brain causes seizures or deficits, which is why cystic echinococcosis is counted among the infections that burden the nervous system ^4,30. The sharpest danger is rupture. If a cyst bursts, whether from a blow or during surgery, its fluid can trigger a violent allergic reaction, up to fatal anaphylaxis, and the spilled protoscoleces can seed dozens of new cysts throughout the abdomen, a complication called secondary hydatidosis ⁴.

Set against its relative, this is the gentler disease. A review of the two describes the cystic form as behaving like a benign tumor of the liver or lung, a thing that grows and displaces but stays within its wall, in contrast to the alveolar form, which behaves like a malignant one ¹³.

The alveolar form: malignant in behavior, benign in cell

Alveolar echinococcosis is the reason this organism belongs in a cancer season. The larva of E. multilocularis does not build a single cyst; it grows as a spongy mass of tiny vesicles that pushes outward into the liver in finger-like projections, with no wall to contain it ^1,25. A World Health Organization (WHO) review states plainly that its growth pattern resembles that of a malignant tumor, with infiltration throughout the liver, spread into neighboring organs, and the formation of metastases in distant organs, so that one of the prevailing differential diagnoses is liver cancer ³. A French review puts it as a slowly developing malignant tumor of the liver, invading the liver's vessels and bile ducts and disseminating to distant sites ¹³.

The resemblance is so close that doctors borrowed the cancer map to chart it. Guided by the TNM system used to stage liver cancer, by which oncologists record the tumor, its spread to nodes and its distant metastases, the WHO group built a parallel PNM system for alveolar echinococcosis: P for the parasitic mass in the liver, N for involvement of neighboring organs, M for metastasis, combined into four stages exactly as in oncology ³. A modern imaging series still describes the disease as infiltrative, tumor-like growth and stages it by this PNM scheme ³¹. Untreated, it is lethal, and because it is silent for years, about seventy percent of patients are already beyond the reach of curative surgery when they are found ^7,23.

And yet it is not a cancer, which is the whole point. A cancer is the host's own cells escaping control through mutation; alveolar echinococcosis is a foreign animal growing in the liver. The cells that divide and infiltrate are the parasite's own germinative stem cells, not transformed human cells, so there is no oncogene, no clonal transformation of the patient's tissue, nothing in the human genome to find ^3,19. This is the paradox worth stating exactly: the disease is malignant in its behavior and benign in its cell. It behaves like a tumor and is read like a tumor, but the thing that is growing is a worm.

The whole history, from antiquity to the cancer map

Echinococcosis is one of the oldest human parasitic diseases on record, with a history that reaches back to antiquity; the fluid cysts of hydatid disease were recognized in patients long before anyone knew a tapeworm lay behind them ³². The science came in the nineteenth century, and it came slowly. The life cycles of the Echinococcus tapeworms were gradually worked out, and the cause of the two human forms was argued over for roughly a hundred years beginning in the middle of that century ³². The decisive step for the alveolar form was taken in 1855, when Rudolf Virchow, the founder of cellular pathology, examined what had until then been called 'alveolar colloid of the liver' and showed it to be an infection with the larval stage of an Echinococcus, setting down the clinical course, the gross appearance and the microscopic findings in detail ³³.

Almost everything a patient is offered today is young. For most of the disease's history the only treatment was the knife. Drug treatment arrived only in 1977, when a benzimidazole, mebendazole, was given to four people with liver hydatid disease and their cysts shrank away on ultrasound over the following months, the first proof that a medicine could kill the parasite inside a living person ³⁴. Imaging advanced alongside it: the first ultrasound classification of hydatid cysts was published by Gharbi and colleagues in 1981, and the needle-drainage approach that became PAIR -- puncture, aspiration, injection and re-aspiration -- was first attempted in the mid-1980s, once it was clear that the puncture long feared for causing fatal anaphylaxis could be done safely ^35,36. In 2003 the World Health Organization issued a single standardized ultrasound classification, the CL and CE1 to CE5 stages still in use, so that a cyst would be staged the same way in every country, and a full expert consensus on diagnosis and treatment followed in 2010 ^10,35.

The thread that brings this worm into a cancer season is more recent again, and the timeline below sets it beside that long clinical history. In 2006 the WHO working group made the resemblance official by giving alveolar echinococcosis a staging system copied from the one used for liver cancer; the parasite's genome and its singular stem cells were read in 2013 and 2014; and the newest work, in 2026, ties the larva's growth to a cancer drug and maps an immune landscape around it that looks like a tumor's, even as the agency that classifies carcinogens still declines to list it ^{3,9,14,19,24,37}.

How many, and where

Cystic echinococcosis is a disease of people who live close to dogs and livestock, and it is found on every inhabited continent ⁴. According to WHO figures, about one million people are living with the cystic disease at any time, carrying an estimated burden of 183,573 disability-adjusted life years, a measure that adds up the years of healthy life lost to illness and early death ⁶. It is concentrated in pastoral regions: rural Africa, the Mediterranean rim, South America, Central Asia and Eastern Europe, and it is endemic across the Middle East and North Africa, where hundreds of millions live at risk ^2,6. WHO lists echinococcosis among both its neglected tropical diseases and its neglected zoonotic diseases ⁶.

Much of the harm never shows up in a human clinic. A systematic review that added human health loss to livestock loss put the worldwide burden of cystic echinococcosis at about 5.9 million zoonosis-DALYs, of which 83% falls on animals, mostly condemned sheep and cattle organs, not people ³⁸. The human numbers themselves are uncertain. A 2025 comparison in China found that the modeled Global Burden of Disease estimate for echinococcosis ran about eleven times higher than the figure from the country's own surveillance, a reminder that the global totals are models built on thin data, not counts ³⁹.

Alveolar echinococcosis is rarer, more lethal, and on the move. It is confined to the northern hemisphere, with roughly 18,000 new cases diagnosed worldwide each year, clustered in parts of China, Central Asia and continental Europe ^7,8. Its range is expanding. A 2025 review documented spread across North America, from 5 to 9 of Canada's 13 provinces and territories and from 13 to 24 of the 50 US states, with a cluster of human and canine cases carrying European-type parasites in Alberta, and first detections in new hosts such as the golden jackal and the eastern chipmunk ⁸. The reservoir is wildlife: one Slovak survey found the fox tapeworm in 35.7% of gray-wolf droppings, rising above half in a protected national park ⁴⁰.

The mimic: a tumor that is not one

The clearest way to see why this parasite belongs in a cancer season is to watch it fool a cancer workup. A 2026 case report describes a 52-year-old man with a hilar liver mass -- a mass at the hilum, the gateway where the vessels and bile ducts enter the liver -- with dilated bile ducts, enlarged lymph nodes and a blood tumor marker, CA19-9, more than seven times the upper limit of normal, a picture that reads as perihilar cholangiocarcinoma, a bile-duct cancer arising around that same gateway ⁴¹. The parasite serology was negative, and the first needle biopsy showed only dead tissue. Only a repeat biopsy, and then surgery, revealed alveolar echinococcosis ⁴¹. The worm had produced every sign of a cancer except the cancer.

This is not a one-off confusion but the expected behavior, written into the disease's own textbooks. Because the alveolar larva infiltrates, invades vessels and bile ducts, and metastasizes, liver cancer is its standard differential diagnosis, and its stage is recorded on a system lifted from oncology ^3,13. The cystic form mimics in a gentler key: a rounded liver or lung cyst can be taken for a cystic tumor, and a ruptured lung cyst, with its mix of fluid and consolidation, is readily mistaken for a lung cancer, which is exactly why patients in these reports were sent for the cancer scan in the first place ^17,42.

The honest framing is the one the brief asks for. This is the parasite that most clearly mimics cancer rather than causing it. It reproduces the radiology, the staging, even the raised tumor marker, and it does none of the biology: no mutation, no transformation of the patient's cells, no cancer. The resemblance is entirely in the behavior of a foreign animal, and the correction is a biopsy, a serology and a parasitologist's eye ^3,41.

The scan that reads the fire, not the worm

The second half of the mimicry happens inside the scanner, and it earns this organism a place beside the FDG-PET page. FDG-PET detects cancer by finding tissue that consumes glucose greedily; it injects a radioactive glucose look-alike and photographs where it piles up. Parasitic lesions light up on it constantly, but, as the PET literature shows, the glow is almost never the worm. In a ruptured lung hydatid sent to exclude cancer, the cyst itself was metabolically silent and the hot signal came from a rim of inflamed lung around it, confirmed against the pathology ¹⁷. The classic appearance is a doughnut: a cold center ringed by a hot margin, seen in 58.8% of one series of proven lung cysts and described again for alveolar liver lesions ^42,43.

The reason is a fact established decades ago in a very different experiment. When researchers inflamed rat tissue with turpentine and traced where the radioactive glucose went, it piled up not in any pathogen but in the host's own inflammatory cells, the young fibroblasts, vessel linings and infiltrating macrophages at the edge of the lesion ²⁶. That is the engine of the false positive here too: in alveolar disease the CD68-marked macrophages crowd the liver next to the parasite and are driven into a glucose-hungry state, so the scan photographs the host's immune bonfire, not the larva ⁴⁴. A 2026 imaging-mass-cytometry map of six human alveolar lesions, from the same Qinghai group, filled in the rest of that immune picture: the liver next to the parasite behaved like the inside of a tumor, with M2 macrophages forming rings around cytotoxic T cells, the T cells thinned out where those macrophages gathered, and focal co-expression of the checkpoint proteins PD-1 and PD-L1 that tumors use to switch off an immune attack -- so the parasite reproduces a cancer's immune landscape as well as its shape, though this was a descriptive study of six patients that makes no claim the worm is or causes cancer ³⁷.

Two consequences follow, and both are traps. First, a negative scan does not mean a dead parasite. A long German follow-up found that alveolar lesions which went metabolically quiet were only suppressed, not killed; activity reappeared after 80 and 82 months, and uptake did not track lesion size or calcification ²⁷. Delayed imaging, taken three hours after injection rather than one, changed the reading in a third of cases, catching activity the standard scan missed ⁴⁵. Second, in cystic disease the signal means even less: a 2021 pilot found no correlation at all between FDG uptake and whether the cyst was alive ¹⁸. FDG-PET remains the reference for judging alveolar activity, hypermetabolic in about 93% of alveolar liver lesions, but what it measures is inflammation, and it must be read as such ^12,46. Read that way it is useful: combined PET and magnetic resonance imaging (MRI) separated lesions responding to albendazole from progressive ones by their uptake, an average SUV of 2.7 against 5.4 ⁴⁷. One recent dynamic-PET study that sharpened the signal carried a commercial conflict of interest, a co-author employed by the scanner maker GE Healthcare ⁴⁸.

The germinative cells: the worm's own stem cells

Underneath the cancer mimicry lies a real question about stem cells, and it is the thread that ties this worm to the season's interest in worm-cancer parallels. The alveolar larva grows forever, which is why one landmark paper titled it the immortal larva. That endless growth is driven by a single cell type: the germinative cells, which are the only cells in the metacestode that can divide, and which give rise to every other, differentiated cell ¹⁹. They closely resemble the neoblasts of free-living flatworms such as planarians, the stem cells that let a planarian regrow from a fragment, and neoblast-like cells have likewise been found in the blood fluke Schistosoma mansoni, so a shared flatworm stem-cell system runs through parasites that live for decades ^19,49.

What makes the comparison to cancer tempting is that these parasite stem cells answer to the same signals that drive human tumors. Human epidermal growth factor, EGF, made by the host, stimulates the worm's germinative cells through the parasite's own EGF receptor and ERK (extracellular signal-regulated kinase) pathway, a chain of growth signals shared across animals, and the receptor was first cloned in 2003 as a relative of the schistosome's own receptor ^23,50. Canonical WNT signaling, a body-patterning pathway central to animal development and to many cancers, governs how the larva forms its vesicles; shutting down the worm's beta-catenin makes its stem cells hyperproliferate ²⁵. The practical upshot is striking: afatinib, a drug designed to block the EGF receptor in human cancers, blocks the parasite's receptor and stunts its growth, and a 2026 study identified the specific receptor, EmER1, that it hits ^23,24.

The parallel must be stated carefully, because it is a parallel and not an identity. These are the worm's genes and the worm's stem cells using signaling grammar shared across animals; they are not evidence that the parasite causes human cancer, and the tapeworm genome has actually discarded several of the stem-cell-fate regulators that other animals, humans included, use to keep growth in check ^9,19. The worm-cancer clusters raise a biological question about how two very different immortal growths lean on the same pathways; they do not make the worm an oncogene. The commercial interest here is also worth noting plainly: part of this EGF-receptor work was done with co-authors from a biotechnology company, Intana Bioscience, developing such inhibitors ²⁴.

How it is found

Cystic echinococcosis is a diagnosis made mostly by picture. The first and most useful tool is abdominal ultrasound, which both finds the cyst and stages it. The WHO Informal Working Group on Echinococcosis built a standard ultrasound classification, the CE1 to CE5 stages, that reads the cyst's biological state from its appearance, running from active fluid cysts, through a transitional stage where the inner membrane detaches, to inactive cysts that are solid or calcified ^10,11. That stage, not just the size, decides treatment, which is why a shared classification matters ¹⁰. Computed tomography (CT) and MRI add the lesion's extent and, in alveolar disease, show its infiltrative margins and the fine microcalcifications that accompany almost all active alveolar lesions ^11,46.

Blood tests play a supporting role and have a known weakness. Antibody serology confirms exposure but is often insensitive, so a negative test does not exclude the disease ⁴. Newer recombinant antigens improve matters: a 2024 fusion-antigen ELISA (enzyme-linked immunosorbent assay, a plate test that measures antibodies to the parasite in a drop of blood) reached 93.8% sensitivity and 83.3% specificity and could tell cystic from alveolar disease, though it still cross-reacted with other parasites 30% of the time ⁵¹. For alveolar disease, antibodies to the recombinant Em18 antigen do more than diagnose; their level tracks how active a lesion is, falling as it responds to treatment ⁵². But serology can fail outright, as in the cholangiocarcinoma mimic whose rEm18 test was negative ⁴¹.

FDG-PET is used not to make the diagnosis but to judge whether an alveolar lesion is still active, and it is the reference test for that purpose, hypermetabolic in about 93% of alveolar liver lesions ^12,46. As the scan-artifact section explains, its signal is host inflammation, so it is read for activity and never as proof of life or death of the parasite ^18,27.

• Abdominal ultrasound (WHO-IWGE staging)The cyst is graded by its look on ultrasound into the WHO-IWGE classes CE1 to CE5, running from active fluid cysts through a transitional stage to inactive, calcified ones ^10,11.The first-line test for cystic disease and the basis for choosing treatment ¹⁰.Defines the stage well, but the ultrasound stage does not always match whether the cyst is biologically alive ¹⁸.Deep or lung cysts, and it cannot reliably tell a dead cyst from a dormant one ^4,18.
• Serology (antibody ELISA; Em18 / rEm18)Blood antibody tests confirm exposure but are often insensitive; recombinant antigens such as Em18 and fusion constructs improve them and help separate the two diseases ^4,51.An adjunct to imaging, and rEm18 antibody levels track how active an alveolar lesion is ⁵².A 2024 fusion-antigen ELISA reached 93.8% sensitivity and 83.3% specificity, with 30% cross-reaction with other parasites ⁵¹.Can read negative even in proven alveolar disease; one cholangiocarcinoma-mimic case was rEm18-negative ⁴¹.
• FDG-PET/CTMeasures the metabolic activity around an alveolar lesion and is used to decide when albendazole can be paused ^12,45.The reference test for alveolar-disease activity, not for making the diagnosis ¹².Hypermetabolic in about 93% of alveolar liver lesions, but the signal is the host's inflammatory rim, so a quiet scan does not mean the parasite is dead ^27,46.Cyst viability in cystic disease, where uptake did not correlate at all in a 2021 series, and it is a classic malignancy mimic when a parasite is not expected ^17,18.
• CT / MRIShow the lesion's extent, its calcification and the infiltrative, tumor-like margins of alveolar disease ^11,31.Staging and surgical planning, graded by the PNM system borrowed from cancer ^3,31.Fine microcalcifications accompany almost all active alveolar lesions on CT ⁴⁶.Cannot by themselves separate alveolar disease from liver cancer, which is why biopsies are repeated ⁴¹.

What is done about it

Treatment of cystic echinococcosis is chosen by the cyst's stage, and the choices are four. The WHO consensus lays out an image-based, stage-specific approach: percutaneous treatment, surgery, drug treatment, or simply watch-and-wait for inactive cysts ¹⁰. The percutaneous option is the PAIR procedure, which stands for puncture, aspiration, injection and re-aspiration: under imaging guidance a needle is passed into the cyst, its fluid is drawn off, a scolex-killing agent such as concentrated saline is injected, and the fluid is drawn off again ⁴. PAIR, introduced over the past few decades, turned many cysts that once needed open surgery into an outpatient procedure, and it is now a validated treatment of cystic disease ^4,13. Surgery, from removing the cyst to resecting part of the organ, remains the option for large or complicated cysts ⁵.

The drug is albendazole, a benzimidazole that poisons the worm's beta-tubulin, the protein of its internal scaffolding ²⁹. Its reach is limited. Albendazole and its relative mebendazole are the only drugs available, and because they are poorly absorbed from the gut their cure rates for cystic disease are only about 30% ²⁸. Real-world results are sobering: in a Chinese program where the drug is free, only 22.9% of patients took it regularly, and among cystic patients followed by imaging within a year, 5.2% met the cure criteria, about a third improved, and most showed no change ⁵³. Albendazole works best as a companion to a procedure, given around PAIR or surgery to lower the risk of spillage and recurrence ^4,10.

Alveolar disease is treated like a cancer that cannot usually be cured. The aim is radical surgery, removing the whole parasitic mass with a clear margin of healthy liver, after which albendazole is given to mop up what is left ^10,13. But because the disease is silent for years, most patients, roughly seventy percent, are found too late for a clean resection, and then the backbone of care is albendazole continued for years or for life, with debulking surgery to relieve symptoms and, in the most advanced cases, liver transplantation ^7,10,13. This is a reversal worth stating plainly: alveolar echinococcosis was once very nearly always fatal, and over the past few decades the alternative treatment procedures, continuous albendazole chief among them, together with earlier diagnosis, have markedly improved patients' survival and quality of life, turning it for most into a controllable chronic disease even though it is still rarely cured outright ^10,13. A 2026 two-center study of 195 resected patients found that leaving out pre-operative albendazole and larger lesions predicted recurrence, confirming that the drug matters even around surgery ⁵⁴. The reason the disease recurs when the drug stops is the germinative cell: these stem cells drive the growth, they survive chemotherapy, and they may carry a form of beta-tubulin that binds the drug poorly ²⁹.

Not a carcinogen, in no IARC group

It is worth saying as plainly as the evidence allows: Echinococcus does not cause cancer, and it is in no IARC group. The International Agency for Research on Cancer classifies agents by how firmly they are shown to cause human cancer, and several parasites have earned its highest category, Group 1. A 2026 IARC analysis of cancer caused by infection lists the twelve Group 1 infectious agents by name, and the parasites among them are the blood fluke Schistosoma haematobium and the liver flukes Opisthorchis viverrini and Clonorchis sinensis ¹⁴. The underlying monograph, the 441-page Volume 100B on biological agents, evaluated those flukes and classified them as carcinogenic to humans ¹⁵. Echinococcus appears on neither list: it has never been evaluated as a carcinogen, because there is no body of evidence that it causes cancer ^14,15.

The contrast with its page-mates is the instructive part. The flukes in Group 1 cause cancer by chronic injury and inflammation of an epithelium they inhabit for years, a mechanism documented in human and animal studies. Echinococcus does nothing of the kind. It is a larva sitting in the parenchyma, the working tissue, of an organ, and the one piece of biology that looks cancerous, the infiltrative growth of the alveolar form, is the parasite's own growth, not a change in the host's cells ^3,19. There is no transformation of human tissue to find, no tumor of the patient's making.

So its place in this season is precise and, in a way, corrective. Where the liver flukes and the schistosome are here as causes of cancer, Echinococcus is here as the opposite: the parasite that counterfeits cancer. It is a mimic on the scan and a mimic on the pathology bench, a tumor-shaped shadow with a worm inside, and nothing in it is carcinogenic ^14,41.

What is still unknown

The hardest numbers are the softest. The global figure of about a million people living with cystic disease is a WHO estimate, and when it has been checked against a country's own surveillance, as in China, the modeled totals have come out many times too high, so the true burden of both forms is genuinely uncertain ^6,39. How fast and how far alveolar disease is spreading as foxes move into cities and across new continents is being tracked in real time, with the North American range still growing ⁸.

The treatment gap is stark. There are still only two old drugs, both poorly absorbed, both holding the parasite rather than killing it, and the cell that matters most, the germinative stem cell, is the one least touched by them ^28,29. Whether the stem-cell biology that makes afatinib and WNT inhibitors work at the bench can become a real therapy, able to kill the larva rather than suspend it, is the open therapeutic question, and it comes trailing commercial interests that should be read carefully ^24,25.

The quieter puzzle is the one the mimicry keeps posing. Why does a flatworm larva grow by the same EGF and WNT signals, and lean on the same host growth factors, that drive the host's own cancers, while carrying none of the mutations that define them ^9,22,23? The worm-cancer parallel is real at the level of pathways and false at the level of cause, and holding both of those facts at once, without overstating the link or dismissing it, is exactly the discipline this organism demands.

Where it connects

Sources

54 sources, numbered as they are cited. Every one was checked against PubMed or its publisher before it was cited here; the note under each says what it shows and what it does not.

1. 1
   Nunnari G, Pinzone MR, Gruttadauria S, Celesia BM, Madeddu G, Malaguarnera G, Pavone P, Cappellani A, Cacopardo B. Hepatic echinococcosis: clinical and therapeutic aspects.World J Gastroenterol · 2012 · 18(13):1448-58doi:10.3748/wjg.v18.i13.1448 · PMID 22509076

   Review. Describes the E. granulosus cyst as a spherical unilocular vesicle with an inner germinal layer and an outer acellular (laminated) layer, a host fibrous pericyst, and daughter cysts in old lesions; states E. multilocularis has a tumor-like infiltrative behavior causing tissue destruction and liver failure; names ultrasonography plus immunodiagnosis, PAIR and benzimidazoles. A review, not new primary data.

2. 2
   Hashemi Shahraki S, Salari Z. Echinococcus granulosus, a Parasite Producing Hydatid Cyst: A Review.Arch Razi Inst · 2025 · 80(3):543-548doi:10.32592/ARI.2025.80.3.543 · PMID 41769286

   Review stating the life cycle uses dogs as definitive hosts and herbivores such as sheep as intermediate hosts, that humans are infected by food or water contaminated with eggs, that cysts form particularly in liver and lungs, and that the disease is prevalent in rural Africa, the Mediterranean, South America, Central Asia and Eastern Europe. General review.

3. 3
   Kern P, Wen H, Sato N, Vuitton DA, Gruener B, Shao Y, Delabrousse E, Kratzer W, Bresson-Hadni S. WHO classification of alveolar echinococcosis: principles and application.Parasitol Int · 2006 · 55 Suppl:S283-7doi:10.1016/j.parint.2005.11.041 · PMID 16343985

   States that the AE growth pattern 'resembles that of a malignant tumor' with infiltration through the liver, spread into neighboring organs and distant metastases, so one prevailing differential diagnosis is liver cancer; describes the PNM staging system (P parasitic mass, N neighboring organs, M metastasis) built by analogy to the TNM system of liver cancer, from 97 and then 222 patients. Describes a clinical classification, not an outcome trial.

4. 4
   Aziz H, Seda P, Aswani Y, Gosse MD, Krishnakumari AJ, Pawlik TM. Cystic echinococcosis of the liver.J Gastrointest Surg · 2025 · 29(3):101974doi:10.1016/j.gassur.2025.101974 · PMID 39864780

   Review searched 1990-2024. States E. granulosus is transmitted by dogs and found on every continent except Antarctica, that humans act as intermediate hosts infected by ingesting eggs, that cysts form typically in liver or lungs, that serum antibody tests have low sensitivity, and that uncomplicated active cysts are treated with chemotherapy with or without PAIR. A narrative review.

5. 5
   Armiñanzas C, Gutiérrez-Cuadra M, Fariñas MC. [Hydatidosis: epidemiological, clinical, diagnostic and therapeutic aspects].Rev Esp Quimioter · 2015 · 28(3):116-24PMID 26032995

   Spanish-language review. States hydatidosis (CE) is caused by E. granulosus with a dog-sheep cycle, has worldwide distribution concentrated in temperate zones, and that treatment rests on three pillars: albendazole, surgery and percutaneous drainage, chosen by symptoms and cyst characteristics. Review; English abstract only.

6. 6
   Borhani M, Fathi S, Lahmar S, Ahmed H, Abdulhameed MF, Fasihi Harandi M. Cystic echinococcosis in the Eastern Mediterranean region: Neglected and prevailing!PLoS Negl Trop Dis · 2020 · 14(5):e0008114doi:10.1371/journal.pntd.0008114 · PMID 32379760

   States that, according to WHO, about one million people worldwide are living with CE with an estimated burden of 183,573 DALYs and an annual monetary burden of about US$3 billion, and that echinococcosis is on WHO's lists of 17 neglected tropical diseases and 12 neglected zoonotic diseases. Restates WHO figures; a regional review.

7. 7
   Polańska-Płachta M, Czerwińska M, Ostrowska M, Stefaniak J, Polański JA. Alveolar Echinococcosis: Is Non-Radical Liver Resection a Game Changer... Single Center Experience of Poland.Acta Parasitol · 2025 · 70(3):100doi:10.1007/s11686-025-01040-z · PMID 40299105

   States about 18,000 new AE cases are diagnosed annually, that AE infiltrates the liver slowly and silently over years, and that about 70% of cases are not eligible for radical resection at diagnosis; complete resection with albendazole is the only curative option, debulking otherwise. A single-center surgical cohort (1995-2017).

8. 8
   Jenkins E, Volappi T, Malone CJ, et al. Changing distribution, diversity, and health impact of Echinococcus multilocularis in Europe and North America.Adv Parasitol · 2025 · 128:159-253doi:10.1016/bs.apar.2025.07.003 · PMID 40947161

   Review of E. multilocularis since 2015. Reports range expansion in North America (from 5 to 9 of 13 Canadian provinces/territories and from 13 to 24 of 50 US states), European-haplotype canine and human cases concentrated in Alberta, a first detection in a golden jackal, and a new rodent host (eastern chipmunk). A narrative One Health review.

9. 9
   Tsai IJ, Zarowiecki M, Holroyd N, et al. The genomes of four tapeworm species reveal adaptations to parasitism.Nature · 2013 · 496(7443):57-63doi:10.1038/nature12031 · PMID 23485966

   Genomes of E. multilocularis, E. granulosus, Taenia solium and Hymenolepis microstoma, 115-141 megabases, showing extreme losses of genes ubiquitous in other animals including 34 homeobox families and several determinants of stem-cell fate, metabolism finely tuned to scavenge host nutrients, and candidate drug targets some already druggable. Primary genomic study.

10. 10
    Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans.Acta Trop · 2010 · 114(1):1-16doi:10.1016/j.actatropica.2009.11.001 · PMID 19931502

    WHO Informal Working Group on Echinococcosis consensus. For CE, an image-based, stage-specific choice among percutaneous treatment, surgery, drugs, or watch-and-wait, using an ultrasound classification. For AE, early radical (tumor-like) surgery with a >2 cm margin plus albendazole, with continuous albendazole as the backbone when radical surgery is impossible; prognosis improved for most AE patients. Expert consensus, not a trial.

11. 11
    Fadel SA, Asmar K, Faraj W, Khalife M, Haddad M, El-Merhi F. Clinical review of liver hydatid disease and its unusual presentations in developing countries.Abdom Radiol (NY) · 2019 · 44(4):1331-1339doi:10.1007/s00261-018-1794-7 · PMID 30306203

    Imaging-focused clinical review emphasizing the WHO ultrasound classification of hepatic echinococcosis and the roles of CT and MRI and serology. A review.

12. 12
    Kratzer W, Steinkellner S, Skotnik D, Peters L, Gruener B, Eberhardt N. Diagnosis of hepatic alveolar echinococcosis: 18F-FDG-PET activity compared to the Echinococcus multilocularis Ulm Ultrasound Classification.Nuklearmedizin · 2025 · 65(1):4-12doi:10.1055/a-2744-4139 · PMID 41326002

    In 121 patients, mean lesion SUVmax was 6.0 (range 2.4-18.0) and differed by ultrasound subtype (pseudocystic 9.2, metastasis-like 3.7); the paper calls FDG-PET/CT the standard for evaluating AE disease activity. A retrospective database analysis.

13. 13
    Bresson-Hadni S, Vuitton DA. [Echinococcoses].Rev Prat · 2001 · 51(19):2091-8PMID 11858156

    French-language review. Contrasts the two diseases: CE evolves as a benign tumor of the liver or lung, AE as a slowly developing malignant tumor of the liver with invasion of liver vessels and bile ducts and metastatic dissemination; states PAIR is a validated treatment of CE, liver transplantation an option in very advanced AE, and high-dose albendazole a necessary complement, lifelong when radical resection is impossible. Review; no PubMed abstract in English beyond this summary.

14. 14
    Rumgay H, Georges D, Huang Y, et al. Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis.Lancet Oncol · 2026 · 27(10):1237-1248doi:10.1016/S1470-2045(26)00307-4 · PMID 42805198

    IARC analysis estimating 2.3 million infection-attributable cancers in 2024 (12% of all cancers) from exactly 12 Group 1 infectious agents it names: H. pylori, HPV, HBV, HCV, EBV, Kaposi's sarcoma herpesvirus, Schistosoma haematobium, HTLV, Opisthorchis viverrini, Clonorchis sinensis, Merkel cell polyomavirus and HIV. Echinococcus is not among them. A worldwide incidence model.

15. 15
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B: A review of human carcinogens.IARC Monogr Eval Carcinog Risks Hum · 2012 · 100(Pt B):1-441PMID 23189750

    The 441-page IARC monograph classifying biological carcinogens; its carcinogenic helminths are the liver flukes Clonorchis sinensis and Opisthorchis viverrini and the blood fluke Schistosoma haematobium. Echinococcus is not evaluated or listed as a carcinogen. Primary document (book volume); PubMed holds the bibliographic record without an abstract.

16. 16
    Santolamazza F, Santoro A, Possenti A, Cacciò SM, Casulli A. A validated method to identify Echinococcus granulosus sensu lato at species level.Infect Genet Evol · 2020 · 85:104575doi:10.1016/j.meegid.2020.104575 · PMID 33007497

    States that E. granulosus sensu lato is a species complex of at least eight genotypes grouped in five species, that genotypes G1 and G3 are the common E. granulosus sensu stricto, and that CE affects more than one million people worldwide. A validated molecular typing method from the EU Reference Laboratory for Parasites.

17. 17
    Yang L, Maldjian PD, Peters S. FDG PET/CT findings of a ruptured pulmonary hydatid cyst with histopathological correlation.Clin Imaging · 2013 · 37(4):798-801doi:10.1016/j.clinimag.2012.12.007 · PMID 23462730

    Case of a man with hemoptysis and suspected lung cancer whose FDG-PET/CT showed absent metabolic activity inside the hydatid cyst and hypermetabolism in the pericystic consolidation, confirmed against histopathology; the first report to correlate these PET findings with pathology. A single case report.

18. 18
    Salvador F, Escolà-Vergé L, Barios M, et al. Usefulness of the FDG PET/CT in the management of cystic echinococcosis: A pilot study.Acta Trop · 2021 · 227:106295doi:10.1016/j.actatropica.2021.106295 · PMID 34954257

    In 16 adults with cystic echinococcosis (WHO stages CE3-CE5), only one cyst showed increased FDG uptake and the single surgically confirmed viable cyst was FDG-negative; the authors found no correlation between FDG-PET and cyst bioactivity. A small prospective pilot.

19. 19
    Koziol U, Rauschendorfer T, Zanon Rodríguez L, Krohne G, Brehm K. The unique stem cell system of the immortal larva of the human parasite Echinococcus multilocularis.EvoDevo · 2014 · 5(1):10doi:10.1186/2041-9139-5-10 · PMID 24602211

    Shows that the germinative cells are the only proliferating cells of the E. multilocularis metacestode, resemble the neoblasts of free-living flatworms, presumably drive the continuous infiltrative growth, and show self-renewal, while conserved stem-cell regulators have been evolutionarily lost. A cell-biology study with molecular markers.

20. 20
    Moudgil P, Lohan A, Nehra AK, Sharma A, Moudgil AD. Molecular characterization of Echinococcus granulosus sensu lato genotypes circulating in small ruminants in north India.Sci Rep · 2026 · 16(1)doi:10.1038/s41598-026-52729-8 · PMID 42141094

    Of 1,049 slaughtered sheep and goats in north India, 85 carried hydatid cysts; genotyping found G1 and G3 (E. granulosus sensu stricto) and G6 (E. canadensis), the first record of small ruminants as intermediate hosts for G6 in India. A regional abattoir survey.

21. 21
    Kashiide T, Kikuta S, Yamaguchi M, Irie T, Kouguchi H, Yagi K, Matsumoto J. Molecular and functional characterization of glucose transporter genes of the fox tapeworm Echinococcus multilocularis.Mol Biochem Parasitol · 2018 · 225:7-14doi:10.1016/j.molbiopara.2018.08.004 · PMID 30130566

    Shows the parasite has no digestive tract and absorbs glucose across its syncytial tegument, and clones two transporters, EmGLUT1 (a functional facilitated glucose transporter) and EmGLUT2, expressed at all life stages. An in-vitro functional study.

22. 22
    Spiliotis M, Tappe D, Sesterhenn L, Brehm K. Long-term in vitro cultivation of Echinococcus multilocularis metacestodes under axenic conditions.Parasitol Res · 2004 · 92(5):430-2doi:10.1007/s00436-003-1046-8 · PMID 14735358

    Shows the parasite larva survives only under low oxygen with reducing agents and grows and forms protoscoleces only in medium preconditioned by hepatoma or other immortal cell lines, i.e. it depends on host-derived growth factors. A culture-method study.

23. 23
    Cheng Z, Liu F, Li X, et al. EGF-mediated EGFR/ERK signaling pathway promotes germinative cell proliferation in Echinococcus multilocularis that contributes to larval growth and development.PLoS Negl Trop Dis · 2017 · 11(2):e0005418doi:10.1371/journal.pntd.0005418 · PMID 28241017

    Calls AE one of the most lethal human helminthic infections and shows that human EGF drives parasite germinative-cell proliferation through the worm's own EGFR/ERK pathway, which is blocked by the EGFR inhibitors CI-1033 and BIBW2992 (afatinib). An in-vitro study.

24. 24
    Koike A, Bergmann M, Cailliau K, Vicogne J, Becker F, Dissous C, Hannus S, Brehm K. A neuregulin-like ligand and EGF receptor underpin Echinococcus multilocularis development.Front Cell Infect Microbiol · 2026 · 16:1742233doi:10.3389/fcimb.2026.1742233 · PMID 41798758

    Identifies the parasite EGF receptor EmER1 as essential for forming metacestode vesicles from germinative cells and as a target of the cancer drug afatinib, plus a parasite neuregulin-like ligand EmNRG regulating stem-cell division. Commercial conflict of interest: two co-authors are at Intana Bioscience GmbH. An in-vitro study.

25. 25
    Herrmann R, Herz M, Rudolf K, Koike A, Spiliotis M, Bergmann M, Holroyd N, Koziol U, Berriman M, Brehm K. Canonical WNT signalling governs Echinococcus metacestode development.PLoS Pathog · 2026 · 22(3):e1014046doi:10.1371/journal.ppat.1014046 · PMID 41871170

    Calls AE a lethal zoonosis caused by the infiltrative growth of the metacestode, and shows that knocking down the parasite's beta-catenin (canonical WNT) impairs vesicle formation and causes stem-cell hyperproliferation, placing a body-patterning pathway at the center of the larva's growth. An RNAi study in primary parasite cell culture.

26. 26
    Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue.J Nucl Med · 1995 · 36(7):1301-6PMID 7790960

    In rats, FDG accumulated most densely not in any pathogen but in the marginal zone of young fibroblasts, vessel endothelium, and infiltrating neutrophils and macrophages of inflamed tissue, establishing that inflammatory cells, not the lesion's cause, drive the FDG signal. An experimental animal autoradiography study.

27. 27
    Reuter S, Grüner B, Buck AK, Blumstein N, Kern P, Reske SN. Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET.Nuklearmedizin · 2008 · 47(4):147-52PMID 18690373

    In 15 AE patients rescanned a median of 6.5 years later, lack of FDG activity indicated suppressed, not dead, parasite: only two of eleven initially inactive lesions stayed permanently inactive, and new activity appeared at 80 and 82 months; activity did not correlate with treatment duration, lesion size or calcification. A small long-term observational study.

28. 28
    Liu CS, Zhang HB, Lei W, Zhang CW, Jiang B, Zheng Q, Yin JH, Han XM. An alternative mebendazole formulation for cystic echinococcosis: the treatment efficacy, pharmacokinetics and safety in mice.Parasit Vectors · 2014 · 7:589doi:10.1186/s13071-014-0589-0 · PMID 25491386

    States that mebendazole and albendazole are the only two drugs used against CE and that their cure rates are only about 30% because of poor oral absorption. A mouse pharmacokinetics/efficacy study; the 30% figure is the cited human background, not this study's result.

29. 29
    Brehm K, Koziol U. On the importance of targeting parasite stem cells in anti-echinococcosis drug development.Parasite · 2014 · 21:72doi:10.1051/parasite/2014070 · PMID 25526547

    Review stating benzimidazoles target parasite beta-tubulin but can only be given at parasitostatic doses with side effects; the germinative (stem) cells drive proliferation and recurrence when chemotherapy stops and may be less benzimidazole-sensitive because they express a beta-tubulin isoform with limited drug affinity. A review proposing stem cells as drug targets.

30. 30
    GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021.Lancet Neurol · 2024 · 23(4):344-381doi:10.1016/S1474-4422(24)00038-3 · PMID 38493795

    Large modeling study that counts cystic echinococcosis among the infectious conditions contributing to nervous-system disease burden, isolating only cases where the central nervous system is damaged. Used here only to note that cysts can involve the brain; a model, not a count of echinococcosis.

31. 31
    Eberhardt N, Haggenmüller B. Sectional Imaging for Alveolar Echinococcosis.Visc Med · 2025 · 41(6):320-327doi:10.1159/000548686 · PMID 41376838

    In 203 patients with suspected AE, describes the disease as infiltrative, tumor-like growth of the liver; FDG-PET was performed in 97.5% and imaging-based PNM staging disagreed with clinical staging in 27.6%, with PET/CT the cornerstone of staging. A retrospective cohort.

32. 32
    Eckert J, Thompson RCA. Historical Aspects of Echinococcosis.Adv Parasitol · 2016 · 95:1-64doi:10.1016/bs.apar.2016.07.003 · PMID 28131361

    Dedicated historical review. States that echinococcosis is a zoonosis whose history dates back to antiquity, and traces the elucidation of the Echinococcus life cycles together with the roughly 100-year controversy over the etiology of the cystic and alveolar forms that began in the middle of the 19th century, as well as the later role of the World Health Organization and international working groups. A history review, not primary data.

33. 33
    Tappe D, Frosch M. Rudolf Virchow and the recognition of alveolar echinococcosis, 1850s.Emerg Infect Dis · 2007 · 13(5):732-5doi:10.3201/eid1305.070216 · PMID 17553252

    Historical article. Recounts that Rudolf Virchow, the founder of cellular pathology, determined in the 1850s that an Echinococcus was the cause of the disease then known as alveolar colloid of the liver, and in his 1855 publication described its clinical course, gross appearance and histopathology in detail. A biographical and historical account.

34. 34
    Bekhti A, Schaaps JP, Capron M, Dessaint JP, Santoro F, Capron A. Treatment of hepatic hydatid disease with mebendazole: preliminary results in four cases.Br Med J · 1977 · 2(6094):1047-51doi:10.1136/bmj.2.6094.1047 · PMID 922416

    The first report of benzimidazole chemotherapy for hydatid disease. Mebendazole given to four patients (three with disease remaining after surgery, one inoperable) produced complete regression of the intrahepatic cysts on ultrasound over four to 13 months, with falling Echinococcus-specific IgE, taken as evidence the drug has a lethal effect on E. granulosus cysts in humans. A four-patient case series. (PubMed records the title with a transcription typo, 'mebedazole'; the published BMJ title and the drug are 'mebendazole'.)

35. 35
    WHO Informal Working Group on Echinococcosis. International classification of ultrasound images in cystic echinococcosis for application in clinical and field epidemiological settings.Acta Trop · 2003 · 85(2):253-61doi:10.1016/s0001-706x(02)00223-1 · PMID 12606104

    The WHO standardized ultrasound classification of cystic echinococcosis (CL, then active CE1-CE2, transitional CE3, and inactive CE4-CE5), built to follow the natural history of the cyst and to standardize treatment across settings. States that it follows the first such classification, developed by Gharbi et al. (Radiology 1981;139:459) and widely used in modified forms since. A standard-setting WHO document.

36. 36
    Giorgio A, Calisti G, de Stefano G, Farella N, Scognamiglio U, Giorgio V. Percutaneous treatment of hydatid liver cysts: an update.Recent Pat Antiinfect Drug Discov · 2012 · 7(3):231-6doi:10.2174/157489112803521913 · PMID 23061784

    Review of percutaneous treatment of liver hydatid disease. States the approach was once discouraged for fear of anaphylaxis after cyst puncture, that following the first uneventful attempts in the mid-1980s these treatments were increasingly used, and that PAIR and its variants were then developed and shown to carry lower morbidity, mortality and recurrence and shorter hospital stays than surgery. A narrative review of the field's history and evidence.

37. 37
    Ma Y, Zhang Y, Zhang T, et al. Imaging mass cytometry of the immune microenvironment in alveolar echinococcosis.Front Cell Infect Microbiol · 2026 · 16:1759455doi:10.3389/fcimb.2026.1759455 · PMID 42180255

    The first spatially resolved map of the human alveolar-echinococcosis immune microenvironment, by imaging mass cytometry of liver tissue from six histologically confirmed patients, comparing lesion-proximal and lesion-distal regions. Found M1/M2 macrophages and dendritic cells forming ring-like structures around cytotoxic-T-cell zones, M2 macrophages inversely correlated with T cells (suggesting T-cell exhaustion), and focal PD-1/PD-L1 checkpoint co-expression with broad CD47 -- an immunosuppressive, tumor-like microenvironment. A descriptive six-patient tissue study that makes no cancer claim.

38. 38
    Noguera Z LP, Charypkhan D, Hartnack S, Torgerson PR, Rüegg SR. The dual burden of animal and human zoonoses: A systematic review.PLoS Negl Trop Dis · 2022 · 16(10):e0010540doi:10.1371/journal.pntd.0010540 · PMID 36240240

    Systematic review combining human and animal loss into zoonosis-DALYs (zDALY). Reports worldwide cystic echinococcosis at 5,935,463 zDALYs (95% CI 4,497,316-7,377,636), of which 83% is animal (livestock) loss. A synthesis of existing estimates, not new field data.

39. 39
    Yang GJ, Ouyang HQ, Zhao ZY, et al. Discrepancies in neglected tropical diseases burden estimates in China: comparative study of real-world data and Global Burden of Disease 2021 data (2004-2020).BMJ · 2025 · 388:e080969doi:10.1136/bmj-2024-080969 · PMID 39965820

    Compares China's reported echinococcosis DALYs with Global Burden of Disease model estimates and finds the GBD figure about 11 times the real-world reported figure, arguing modeled global estimates can diverge from surveillance data. A comparative study of reported versus modeled data.

40. 40
    Jarošová J, Antolová D, Šnábel V, et al. The fox tapeworm, Echinococcus multilocularis, in grey wolves and dogs in Slovakia: epidemiology and genetic analysis.J Helminthol · 2020 · 94:e168doi:10.1017/S0022149X20000528 · PMID 32624011

    Detected E. multilocularis DNA in 35.7% of 112 gray-wolf fecal samples (up to 51.2% in one national park) and 2.7% of 110 dog samples in Slovakia, all European-type haplotypes, confirming wide wildlife circulation. A fecal-DNA survey in carnivores.

41. 41
    Wang Y, Dong T, Yang D, Xu S, Nie F. Hepatic alveolar echinococcosis mimicking cholangiocarcinoma: a case study.BMC Infect Dis · 2026 · 26(1)doi:10.1186/s12879-026-12892-9 · PMID 41882584

    A 52-year-old man's hilar liver mass with bile-duct dilation, enlarged nodes and CA19-9 more than seven times the upper limit mimicked perihilar cholangiocarcinoma; the rEm18-ELISA was negative and the first biopsy showed only necrosis, so a repeat biopsy was needed to prove alveolar echinococcosis. A single case report.

42. 42
    Yoldaş B, Gürsoy S, Budak E, et al. FDG PET/CT signs of proven pulmonary hydatid cyst: is there any clue?Jpn J Radiol · 2022 · 40(11):1194-1200doi:10.1007/s11604-022-01296-9 · PMID 35727457

    In 17 proven pulmonary hydatid cysts previously scanned to exclude malignancy, SUVmax ranged 0.5 to 15.8 (mean 4.68); five were FDG-negative, two focal, and ten (58.8%) showed the doughnut sign of a hot rim around a cold center. A small retrospective series.

43. 43
    Shen G, Kou Y, Kuang A. Doughnut sign of hepatic alveolar echinococcosis on FDG PET/CT: Clinical case report.Medicine (Baltimore) · 2019 · 98(8):e14561doi:10.1097/MD.0000000000014561 · PMID 30813170

    A young man's hepatic AE showed central necrosis with a rim of solid inflammatory tissue producing the doughnut sign on FDG-PET/CT; treated by resection and benzimidazoles with no recurrence at two years. A single case report.

44. 44
    Zhang T, Zhang Y, Yang Z, et al. Echinococcus protoscoleces enhance glycolysis to promote M2 macrophages through PI3K/Akt/mTOR signaling pathway.Pathog Glob Health · 2022 · 117(4):409-416doi:10.1080/20477724.2022.2104055 · PMID 35876088

    Finds CD68-positive macrophages gathered in liver tissue next to human AE lesions, and shows parasite protoscoleces push macrophages toward the M2 state with raised glycolytic enzymes (HK1, PFKL, PKM2) via PI3K/Akt/mTOR, evidence that the FDG-avid metabolism around the lesion is largely the host's immune cells. An in-vitro and tissue study.

45. 45
    Caoduro C, Porot C, Vuitton DA, Bresson-Hadni S, Grenouillet F, Richou C, Boulahdour H, Blagosklonov O. The role of delayed 18F-FDG PET imaging in the follow-up of patients with alveolar echinococcosis.J Nucl Med · 2013 · 54(3):358-63doi:10.2967/jnumed.112.109942 · PMID 23303963

    In 120 scans of 70 benzimidazole-treated AE patients, delayed (3-hour) imaging changed interpretation in 32.5% of cases, revealing perilesional uptake missed at standard acquisition, and the parasite could stay viable even when standard uptake had vanished. A prospective single-center study.

46. 46
    Brumpt E, Blagosklonov O, Calame P, Bresson-Hadni S, Vuitton DA, Delabrousse E. AE hepatic lesions: correlation between calcifications at CT and FDG-PET/CT metabolic activity.Infection · 2019 · 47(6):955-960doi:10.1007/s15010-019-01328-z · PMID 31165442

    In 61 patients, 93% (57/61) of alveolar hepatic lesions were hypermetabolic on FDG-PET/CT and microcalcifications were present in 95%, with hypermetabolic activity strongly correlated to microcalcification. A single-center imaging correlation study.

47. 47
    Eberhardt N, Peters L, Kapp-Schwoerer S, Beer M, Beer AJ, Grüner B, Thaiss WM. 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting.Pathogens · 2022 · 11(3):348doi:10.3390/pathogens11030348 · PMID 35335672

    In 51 AE patients, FDG uptake separated benzimidazole responders from progressive lesions (SUVavg 2.7 vs 5.4, p<0.001), while diffusion MRI did not; PET/MR gave the metabolic read at a lower radiation dose. A retrospective imaging study.

48. 48
    Husmann L, Sah BR, Kotasidis F, Maurer A, Meyer zu Schwabedissen C, Deibel A, Huellner MW. Whole-body dynamic FDG-PET/CT parametric imaging in alveolar echinococcosis.Ann Nucl Med · 2025 · 40(2):154-161doi:10.1007/s12149-025-02113-9 · PMID 41051686

    In 20 AE datasets, lesion SUVmax (5.7) exceeded normal liver (3.2) and the metabolized-FDG (Patlak) ratio correlated with hydatid-fluid antibody levels, giving higher lesion contrast. Commercial conflict of interest: co-author Fotis Kotasidis is affiliated with GE Healthcare. A small prospective methods study.

49. 49
    Collins JJ 3rd, Wang B, Lambrus BG, Tharp ME, Iyer H, Newmark PA. Adult somatic stem cells in the human parasite Schistosoma mansoni.Nature · 2013 · 494(7438):476-9doi:10.1038/nature11924 · PMID 23426263

    Describes neoblast-like somatic stem cells in the blood fluke Schistosoma mansoni that resemble planarian neoblasts, proliferate and differentiate into multiple cell types and require an FGF-receptor gene, offered here as the comparative flatworm case to Echinococcus germinative cells. A primary study in a different parasite.

50. 50
    Spiliotis M, Kroner A, Brehm K. Identification, molecular characterization and expression of the gene encoding the epidermal growth factor receptor orthologue from the fox-tapeworm Echinococcus multilocularis.Gene · 2003 · 323:57-65doi:10.1016/j.gene.2003.09.007 · PMID 14659879

    First cloning of the E. multilocularis EGF-receptor tyrosine kinase EmER, most similar to the Schistosoma mansoni receptor SER, a single-copy gene expressed in the larva and about ten-fold higher in the protoscolex. A molecular characterization.

51. 51
    Yang X, Wang T, Chen Y, Wang W. Expression and serodiagnostic efficacy of a novel echinococcosis-specific recombinant fusion antigen rAgB8/1-Em18-Eg95.Parasitology · 2024 · 151(13):1458-1465doi:10.1017/S0031182024001173 · PMID 39623586

    A recombinant fusion-antigen ELISA (T3) tested on 272 confirmed cases gave 93.8% sensitivity and 83.3% specificity, with 30% cross-reaction with other parasites, and distinguished cystic from alveolar echinococcosis. A single laboratory evaluation of a new antigen.

52. 52
    Simon G, Grenouillet F, Richou C, et al. Correlation between imaging features and rEm18 antibodies in alveolar echinococcosis: results from a multicenter study in France.Parasite · 2025 · 32:8doi:10.1051/parasite/2024076 · PMID 39918234

    In 45 AE patients from the French EchinoVISTA cohort, a higher recombinant-Em18 antibody index was associated with larger lesions, more microcysts and higher FDG-PET SUV, and serologic responders at two years had smaller lesions and lower baseline antibody. A retrospective analysis within a prospective cohort.

53. 53
    Qin M, Yang G, Yan J, et al. Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis.Infect Dis Poverty · 2024 · 13(1):98doi:10.1186/s40249-024-01268-3 · PMID 39707489

    Of 582 evaluable albendazole-treated patients across 10 endemic Chinese counties, only 22.9% took the drug regularly; among 174 CE patients with imaging follow-up within a year, 5.2% met cure criteria, 32.2% improved, 59.8% were ineffective and 2.9% recurred. A real-world compliance survey.

54. 54
    Rrupa D, Kaiser C, Melloul E, Uldry E, Halkic N, Beldi G, Gloor S, Lachenmayer A, Joliat GR. Long-Term Outcomes After Hepatectomy for Alveolar Echinococcosis in Immunosuppressed Patients.Pathogens · 2026 · 15(7):756doi:10.3390/pathogens15070756 · PMID 42515083

    In 195 patients resected for liver AE in two hospitals (2000-2021), preoperative albendazole was given in 57% and recurrence occurred in 10 over a median 58 months; absence of preoperative albendazole and larger lesion size predicted recurrence, and immunosuppression did not. A bicentric retrospective study.